Octreotide injections

Octreotide is used at Great Ormond Street Hospital (GOSH) to treat persistently low blood sugar levels (hypoglycaemia) caused by the body producing too much insulin (hyperinsulinism).

It is a man-made version of the natural hormone, somatostatin, which stops certain cells in the pancreas releasing insulin. It can be used alone or together with the medicines diazoxide and chlorothiazide as directed by your child’s doctor.

The use of octreotide in children is not currently licensed in the UK. Medicines are often used outside of their license (off-label) in children because trial data is not available for a specific use. This is not necessarily hazardous but should be explained and agreed before use. Your doctor will explain this further to you.

Octreotide for injection is available as different strengths, which can be injected under the skin (subcutaenously). At GOSH, we use a multi-dose vial, which can be used for up to 10 injections. The strength of this injection solution is 1mg of active ingredient in 5ml of liquid. The solution also contains water and preservatives.

How is octreotide given?

Octreotide is given as a subcutaneous injection, three to four times a day. The dose should be calculated in millilitres, drawn up from the multi-dose vial and given using a BD insulin syringe.

Who should not use octreotide injections?

People with the following conditions should discuss taking these medicines with their doctor:

  • Hypersensitivity to octreotide or any of its ingredients.
  • Pregnant, could be pregnant, trying to become pregnant or breastfeeding.

What are the side effects of octreotide?

If any of these side effects are severe or carry on for a long time, please tell your doctor:

  • Skin reactions affecting the injection site.
  • Loss of appetite, sickness, tummy pain, bloating and/or diarrhoea.
  • Gall bladder or liver problems, possibly showing as yellowing of the skin or whites of the eyes.
  • Hair loss.

Octreotide and interactions with other medicines

Some medicines can react with octreotide, altering how well they work. Always check with your doctor or pharmacist before giving your child any other medicines, including herbal or complementary medicines. The following are known to react with octreotide:

  • ciclosporin
  • anti-diabetic medicines such as insulin or metformin
  • anti-reflux medicines, particularly cimetidine

Important information about octreotide

  • Keep medicines in a safe place where children cannot reach them.
  • Keep the injection ampoules in the fridge in their original packaging. They should be taken out of the fridge and kept at room temperature for giving the injections. They will keep at room temperature for up to two weeks.
  • If you are using the multi-dose vial, you should also keep this in the fridge but take it out an hour before giving an injection so it reaches room temperature. Do not use this vial more than 10 times.
  • If you forget to give your child a dose, and it is within a few hours of when the dose was due, give it as soon as you remember. Otherwise, do not give this dose but wait until the next dose is due. Do not give a double dose.
  • If your doctor decides that your child should stop having these injections, or they pass the expiry date, return any remaining vials or ampoules to your pharmacist. Do not flush them down the toilet or throw them away.
Compiled by: 
The Pharmacy and Endocrinology departments in collaboration with the Child and Family Information Group.
Last review date: 
January 2014
Ref: 
2013F0870

Disclaimer

Please read this information sheet from GOSH alongside the patient information leaflet (PIL) provided by the manufacturer. If you do not have a copy of the manufacturer’s patient information leaflet please talk to your pharmacist. A few products do not have a marketing authorisation (licence) as a medicine and therefore there is no PIL.

For children in particular, there may be conflicts of information between the manufacturer’s patient information leaflet (PIL) and guidance provided by GOSH and other healthcare providers. For example, some manufacturers may recommend, in the patient information leaflet, that a medicine is not given to children aged under 12 years. In most cases, this is because the manufacturer will recruit adults to clinical trials in the first instance and therefore the initial marketing authorisation (licence) only covers adults and older children.  

For new medicines, the manufacturer then has to recruit children and newborns into trials (unless the medicine is not going to be used in children and newborns) and subsequently amend the PIL with the approved information. Older medicines may have been used effectively for many years in children without problems but the manufacturer has not been required to collect data and amend the licence. This does not mean that it is unsafe for children and young people to be prescribed such a medicine ‘off-licence/off-label’. However, if you are concerned about any conflicts of information, please discuss with your doctor, nurse or pharmacist.